Human papillomavirus vaccines for cervical cancer

Journal of Immunotherapy

Volumn 22, Issue 3, 1999, Pages 212-218

  Murakami, Masaru ^a,b   Gurski, Karen J ^a   Steller, Michael A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cervical cancer; Human papillomavirus; Vaccine

Indexed keywords

VIRUS VACCINE;

CANCER PREVENTION; FEMALE; HUMAN; IMMUNOPROPHYLAXIS; PRIORITY JOURNAL; REVIEW; UTERINE CERVICITIS; UTERINE CERVIX CANCER; VACCINATION; VIRUS CARCINOGENESIS; VIRUS INFECTION; WART VIRUS;

ANIMALS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0032940888     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199905000-00003     Document Type: Article

References (60)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
2. Piver MS. Handbook of gynecologic oncology. Boston: Little, Brown, 1996.
3. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9.
4. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments], J Natl Cancer Inst 1995;87:796-802.
5. de Villiers EM. Heterogeneity of the human papillomavirus group. J Virol 1989;63:4898-903.
6. Pecoraro G, Morgan D, Defendi V. Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci USA 1989;86:563-7.
7. Barbosa MS, Vass WC, Lowy DR, Schiller JT. In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol 1991;65:292-8.
8. Munger K, Scheffner M, Huibregtse JM, Howley PM. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 1992;12:197-217.
9. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
10. Howley PM. Papillomavirinae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fundamental virology. Philadelphia: Lippincott-Raven, 1996:947-78.
11. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
12. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J 1989;8:513-9.
13. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long-term follow-up. Obstet Gynecol 1986;67:665-9.
14. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990;38:377-82.
15. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994;54:4610-3.
16. Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, Veldhuizen RW, Fleuren GJ. Association between HLA-expression and infiltration of immune cells in cervical carcinoma [see comments]. Lab Invest 1993;69:651-9.
17. Schiffman MH. Epidemiology of cervical human papillomaviruses. In: zur Hausen H, ed. Human pathogenic papillomaviruses. Heidelberg: Springer-Verlag, 1994.
18. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr Opin Immunol 1993;5:27-34.
19. Whalen RG, Davis HL. DNA-mediated immunization and the energetic immune response to hepatitis B surface antigen. Clin Immunol Immunopathol 1995;75:1-12.
20. Schiller JT, Okun MM. Papillomavirus vaccines: current status and future prospects. Adv Dermatol 1996; 11:355-80; discussion: 355-80; discussion: 381.
21. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus LI major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 1992;89:12180-4.
22. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, et al. Efficient self-assembly of human papillomavirus type 16 LI and L1-L2 into virus-like particles. J Virol 1993;67:6929-6936.
23. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, et al. Systemic immunization with papillomavirus LI protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-11557.
24. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol 1996;70:3298-3301.
25. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, St. `Louis, ME, et al. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis 1995;172:1584-1587.
26. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995;154:5934-5943.
27. Pardoll DM. Genetically engineered tumor vaccines. Ann NY Acad Sci 1997.
28. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992;58:143-75:143-175.
29. Melief CJ, Kast WM. Lessons from T cell responses to virus induced tumours for cancer eradication in general. Cancer Surv 1992;13:81-99.
30. Roitt I, Brostoff J, Male D. Cells involved in the immune response. F. Foley, L. van den Bergh and C. Welcomme (eds), Immunology, pp. 1-18, New York: 1989.
31. Steinman RM, Witmer-Pack M, Inaba K. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 1993;329:1-9.
32. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-110.
33. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996;156:2918-2926.
34. Zinkernagel RM. Immunology taught by viruses [see comments]. Science 1996;271:173-178.
35. Old LJ. Immunotherapy for cancer. Sci Am 1996;275:136-143.
36. Irvine KR, Restifo NP. The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 1995;6:337-347.
37. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-3912.
38. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Longh BM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-2249.
39. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, et al. Generation of tumor specific cytolytic T-lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic HPV-16 E7 epitope. Am J Obstet Gynecol 1996;175:1586-1593.
40. Steller MA, Schiller IT. Human papillomavirus immunology and vaccine prospects. J Natl Cancer Inst Monogr 1996;21:145-148.
41. Steller MA, Gurski KI, Murakami M, et al. Cell mediated immunologic responses in cervical and vaginal cancer patients with a lipidated epitope of HPV-16 E7. Clin Cancer Res 1998;4:2103-9.
42. Feltkamp MC, Vreugdenhil GR, Vierboom MP, et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
43. Keating PI, Cromme FV, Duggan-Keen M, Snijders PI, Walboomers IM, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. BrJ Cancer 1995;72:405-411.
44. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
45. van Driel WJ, Tjiong MY, Hilders CG, Trimbos BJ, Fleuren GJ. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma. Gynecol Oncol 1996;62:33-41.
46. Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter [published erratum appears in Science 1994 Apr 1; 264(5155): 16]. Science 1993;261:769-771.
47. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape [see comments]. Science 1996;274:1363-1366.
48. Restifo NP. The new vaccines: building viruses that elicit antitumor immunity. Curr Opin Immunol 1996;8:658-663.
49. Alexander I, Sidney J, Southwood S, Ruppert J, Oseroff C, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-761.
50. Trudel M, Nadon F, Seguin C, Brault S, Lusignan Y, et al. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 1992;10:107-112.
51. Morein B. The iscom antigen-presenting system. Nature 1988;332:287-288.
52. Fernando GJ, Stenzel DJ, Tindle RW, Merza MS, Morein B, et al. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 1995;13:1460-1467.
53. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996;74:8-25.
54. Martinez-Kinader B, Lipford GB, Wagner H, Heeg K. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway. Immunology 1995;86:287-295.
55. Schirmbeck R, Demi L, Melber K, Wolf H, Wagner R, et al. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 1995;13:857-865.
56. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982;79:7415-7419.
57. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [see comments]. Lancet 1996;347:1523-1527.
58. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J Immunol 1995;154:4651-7.
59. Wu TC, Guarnieri FG, Staveley-O’Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92:11671-5.
60. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.